JBF Capital’s Insys Therapeutics, Inc. INSY Stock Holding History

JBF Capital’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-100,000	Closed	-$350K	–	104
2018 Q4	$350K	Buy	+100,000	New	+$695K	0.07%	39

Other funds holding INSY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

JBF Capital's INSY Position: Q1 2019 in Review

JBF Capital sold out of Insys Therapeutics, Inc. (INSY) in Q1 2019, closing a stake of 100,000 shares — an estimated $350K sold.

JBF Capital first reported a position in INSY in Q4 2018 and held it in 1 quarter. The position peaked at $350K in Q4 2018. 98 funds tracked by Wall St. Rank hold INSY as of Q1 2019.

JBF Capital reported no remaining Insys Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
JBF Capital sold 100,000 Insys Therapeutics, Inc. shares in Q1 2019, an estimated $350K.
JBF Capital first reported a position in Insys Therapeutics, Inc. in Q4 2018 and held it in 1 quarter.
JBF Capital's Insys Therapeutics, Inc. position peaked at $350K in Q4 2018.
98 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2019.

Based on JBF Capital's 13F filing for Q1 2019, filed 7 May 2019.